SG11202000098RA - Polymorphic forms of dasatinib - Google Patents
Polymorphic forms of dasatinibInfo
- Publication number
- SG11202000098RA SG11202000098RA SG11202000098RA SG11202000098RA SG11202000098RA SG 11202000098R A SG11202000098R A SG 11202000098RA SG 11202000098R A SG11202000098R A SG 11202000098RA SG 11202000098R A SG11202000098R A SG 11202000098RA SG 11202000098R A SG11202000098R A SG 11202000098RA
- Authority
- SG
- Singapore
- Prior art keywords
- dasatinib
- international
- present
- butanediol
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
21heta - Scale Figure 3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) oviolo Ina oimIE (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2019/008555 Al (43) International Publication Date 10 January 2019 (10.01.2019) WIPO I PCT Uttara Kannada 581327 (IN). RAGHUNADHACHET- TY, Jithendrababu; No .7-138/D/10, Aragonda, Tha- vanam Palli Mandal, Andhra Pradesh, Chittoor District 517129 (IN). KALIAPPAN, Mariappan; Sri Sangili Matha Stores, Keelakuyilkudi Villakku, Theni Main Road, Nagamalai, Tamilnadu, Madurai 625019 (IN). PALLE, Venkata, Raghavendracharyulu; 194/A, Mythri Nagar, Madinaguda, Miyapur, Telangana, Hyderabad 500049 (IN). REGALLA, VijayBhaskar, Reddy; H.No: 1-102-1, Cha- trai (mandal & Post), Burugugudem Road, Andhra Pradesh, Krishna District 521214 (IN). (74) Agent: MAJUMDAR, Subhatosh et al.; S. Majumdar & Co., 5, Harish Mukherjee Road, West Bengal, Kolkata 700 025 (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (51) International Patent Classification: CO7D 417/12 (2006.01) (21) International Application Number: PCT/IB2018/055022 07 July 2018 (07.07.2018) English English (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 201741024067 07 July 2017 (07.07.2017) IN 201741029965 24 August 2017 (24.08.2017) IN 201841001249 11 January 2018 (11.01.2018) IN 201841007613 28 February 2018 (28.02.2018) IN (71) Applicant: BIOCON LIMITED [IN/IN]; 20th KM, Hosur Road, Electronic City, Karnataka, Bangalore 560 100 (IN). (72) Inventors: BHAT, Ramakrishna, Parameshwar; Kadekodi, Po: Dhareshwar, Ta: Kumta, Karnataka, Dist: (54) Title: POLYMORPHIC FORMS OF DASATINIB 15<x.2' n.f)f) 11 C 9000 anon r•-• .• W O 20 19/008555 Al (57) : The present invention provides for the dasatinib- thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(f) — 1, 2-Butane diol, crystalline dasatinib (R)-1, 2-Butanediol, crystalline dasatinib (S)-1, 2-Butanediol and crystalline dasatinib (±)-2, 3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib- butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib. The present invention also provides for a process for preparation of dasatinib monohydrate from anhydrous dasatinib [Continued on next page] WO 2019/008555 Al MIDEDIMOMOIDEIROMOIDOVIIMHEMMODEVOIMIE KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741024067 | 2017-07-07 | ||
| IN201741029965 | 2017-08-24 | ||
| IN201841001249 | 2018-01-11 | ||
| IN201841007613 | 2018-02-28 | ||
| PCT/IB2018/055022 WO2019008555A1 (en) | 2017-07-07 | 2018-07-07 | Polymorphic forms of dasatinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000098RA true SG11202000098RA (en) | 2020-02-27 |
Family
ID=64949779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000098RA SG11202000098RA (en) | 2017-07-07 | 2018-07-07 | Polymorphic forms of dasatinib |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11059813B2 (en) |
| EP (1) | EP3649126A4 (en) |
| JP (1) | JP2020526528A (en) |
| KR (1) | KR20200036867A (en) |
| CN (1) | CN111108104A (en) |
| AU (1) | AU2018297710A1 (en) |
| BR (1) | BR112020000302A2 (en) |
| CA (1) | CA3069107A1 (en) |
| MX (1) | MX2020000185A (en) |
| RU (1) | RU2020105723A (en) |
| SG (1) | SG11202000098RA (en) |
| WO (1) | WO2019008555A1 (en) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01010292A (en) | 1999-04-15 | 2002-10-23 | Squibb Bristol Myers Co | Cyclic protein tyrosine kinase inhibitors. |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| TWI338004B (en) * | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| EP1937270A1 (en) | 2005-09-21 | 2008-07-02 | Brystol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
| EP2508523B2 (en) * | 2007-10-23 | 2019-04-17 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
| WO2010062715A2 (en) | 2008-11-03 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
| WO2010067374A2 (en) | 2008-12-08 | 2010-06-17 | Hetero Research Foundation | Polymorphs of dasatinib |
| CN102040596A (en) * | 2009-10-10 | 2011-05-04 | 上海希迪制药有限公司 | Dasatinib polymorph and preparation method thereof |
| CN102030745B (en) | 2010-11-26 | 2012-05-09 | 江苏先声药物研究有限公司 | Dasatinib solvate and preparation method thereof |
| CN102086195B (en) * | 2011-01-28 | 2013-04-03 | 南京卡文迪许生物工程技术有限公司 | Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof |
| ES2637829T3 (en) | 2012-06-15 | 2017-10-17 | Basf Se | Multi-component crystals comprising dasatinib and selected co-crystal forming agents |
| CZ306598B6 (en) * | 2012-12-06 | 2017-03-22 | Zentiva, K.S. | A method of preparation and purification of new and known polymorphs and dasatinib solvates |
| WO2015049645A2 (en) * | 2013-10-04 | 2015-04-09 | Alembic Pharmaceuticals Limited | An improved process for the preparation of dasatinib |
| EP3160963A1 (en) * | 2014-06-30 | 2017-05-03 | Basf Se | Multicomponent crystals of dasatinib with menthol or vanillin |
| EP3186284B1 (en) | 2014-08-28 | 2022-04-06 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
| WO2016178148A1 (en) * | 2015-05-05 | 2016-11-10 | Glenmark Pharmaceuticals Limited | Process for preparation of dapagliflozin |
| US10301302B2 (en) * | 2015-06-29 | 2019-05-28 | Msn Laboratories Private Limited | Crystalline forms of N-(2-chloro-6-methy]phenvn-2-[F6-[4-(2-hvdroxvethvl)-L-piperazin-vil-2-methvil-4-pvrimidinvllaminol-5-thiazolecarboxamide and their process thereof |
| US9845303B2 (en) * | 2015-10-19 | 2017-12-19 | Cadila Healthcare Limited | Process for the preparation of dapagliflozin |
| WO2017098391A1 (en) | 2015-12-11 | 2017-06-15 | Shilpa Medicare Limited | Process for the preparation of dasatinib |
| WO2017134617A1 (en) * | 2016-02-03 | 2017-08-10 | Dr. Reddy's Laboratories Limited | Process for the preparation of amorphous dasatinib |
| US10464933B2 (en) * | 2016-02-03 | 2019-11-05 | Dr. Reddy's Laboratories Limited | Solid state forms of dasatinib and processes for their preparation |
-
2018
- 2018-07-07 US US16/628,746 patent/US11059813B2/en active Active
- 2018-07-07 EP EP18827395.7A patent/EP3649126A4/en not_active Withdrawn
- 2018-07-07 RU RU2020105723A patent/RU2020105723A/en unknown
- 2018-07-07 WO PCT/IB2018/055022 patent/WO2019008555A1/en unknown
- 2018-07-07 CA CA3069107A patent/CA3069107A1/en not_active Abandoned
- 2018-07-07 JP JP2020500624A patent/JP2020526528A/en active Pending
- 2018-07-07 MX MX2020000185A patent/MX2020000185A/en unknown
- 2018-07-07 BR BR112020000302-6A patent/BR112020000302A2/en not_active Application Discontinuation
- 2018-07-07 KR KR1020207003800A patent/KR20200036867A/en not_active Application Discontinuation
- 2018-07-07 SG SG11202000098RA patent/SG11202000098RA/en unknown
- 2018-07-07 CN CN201880058510.0A patent/CN111108104A/en active Pending
- 2018-07-07 AU AU2018297710A patent/AU2018297710A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3649126A4 (en) | 2021-04-07 |
| EP3649126A1 (en) | 2020-05-13 |
| BR112020000302A2 (en) | 2020-07-14 |
| JP2020526528A (en) | 2020-08-31 |
| CN111108104A (en) | 2020-05-05 |
| US20200377495A1 (en) | 2020-12-03 |
| MX2020000185A (en) | 2021-01-29 |
| CA3069107A1 (en) | 2019-01-10 |
| RU2020105723A (en) | 2021-08-09 |
| AU2018297710A2 (en) | 2020-03-05 |
| AU2018297710A1 (en) | 2020-02-27 |
| WO2019008555A1 (en) | 2019-01-10 |
| KR20200036867A (en) | 2020-04-07 |
| US11059813B2 (en) | 2021-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201909541WA (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201806758VA (en) | Vcn enhancer compositions and methods of using the same | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201900634VA (en) | Chimeric antigen receptor | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201811015RA (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| SG11201407458XA (en) | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | |
| SG11201807881VA (en) | Compositions and methods for making antibodies based on use of an expression-enhancing locus | |
| SG11201900609PA (en) | Method and system for providing buffer solutions | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201810975UA (en) | Method for stabilizing proteins | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201901140QA (en) | Compounds and methods for reducing tau expression | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201906552WA (en) | TGF-ß DECOY RECEPTOR | |
| SG11201807885PA (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |